<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984035</url>
  </required_header>
  <id_info>
    <org_study_id>09-135-B</org_study_id>
    <nct_id>NCT00984035</nct_id>
  </id_info>
  <brief_title>Investigation of Cisplatin-Related Kidney Toxicity</brief_title>
  <official_title>Investigation of Germline Genetic Determinants and Early Biomarkers of Cisplatin-Related Nephrotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society of Clinical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify novel biomarkers of kidney injury in patients
      receiving cisplatin.

      This study will also collect DNA for future analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will look for novel biomarkers of kidney injury in patients receiving cisplatin in
      patients currently receiving cisplatin.

      DNA will be collected both prospectively and retrospectively (from patients that have
      previously received cisplatin.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 22, 2009</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urine biomarker (NGAL) after cisplatin</measure>
    <time_frame>while on drug and up to 35 days after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood and urine cystatin C</measure>
    <time_frame>while on drug and up to 35 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood NGAL while receiving cisplatin</measure>
    <time_frame>while on drug and up to 35 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic markers of kidney toxicity</measure>
    <time_frame>while on drug and up to 35 days after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">341</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Prospecitive Analysis</arm_group_label>
    <description>Patients currently receiving cisplatin as treatment for their cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrospective Analysis</arm_group_label>
    <description>Patients that have previously received cisplatin as treatment for their cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine samples (biomarkers)</intervention_name>
    <description>Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.</description>
    <arm_group_label>Prospecitive Analysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples (biomarkers)</intervention_name>
    <description>blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.</description>
    <arm_group_label>Prospecitive Analysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample (DNA)</intervention_name>
    <description>Blood sample collected for DNA analysis at anytime while on-study.</description>
    <arm_group_label>Prospecitive Analysis</arm_group_label>
    <arm_group_label>Restrospective Analysis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Blood Serum/Plasma Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving anti-cancer treatment with cisplatin (or previously treated with
        cisplatin) at a participating academic medical center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Prospective Analysis Group

        Inclusion Criteria:

          -  Patients about to receive intravenous cisplatin for the first time as part of cancer
             chemotherapy.

          -  Aged 18 years and older.

          -  Ability to understand and willingness to sign a written consent document.

          -  Patients may be receiving cisplatin in combination with other chemotherapeutic agents.

          -  Patients may be receiving cisplatin in the context of another clinical trial.

        Exclusion Criteria:

          -  Prior receipt of cisplatin.

          -  Patients on dialysis or other renal replacement therapy prior to starting cisplatin.

          -  Uncontrolled hypo- or hyperthyroidism (patients on chronic stable doses of thyroid
             replacement medication are eligible).

        Retrospective Analysis Group

        Inclusion Criteria:

          -  Patients that have previously received intravenous cisplatin as part of cancer
             chemotherapy.

          -  Aged 18 years and older.

          -  Ability to understand and willingness to sign a written consent document.

          -  Patients that received cisplatin in combination with other chemotherapeutic agents are
             eligible.

          -  Patients that received cisplatin in the context of a clinical trial are eligible.

        Exclusion Criteria:

          -  Unable or unwilling to submit to a one-time blood draw.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter H O'Donnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

